In 2001, Professor Stasch, JP pointed out a novel compound capable of effectively stimulating sGC independent of the NO mechanism, suggesting a new potential for cardiovascular disease treatment (Stasch et al., 2001). This evidence concerns the gene SGCB and cardiovascular disorder.